A correlation between expression of the glucose-regulated protein of 78 kDa (GRP78) in malignant melanoma tumors and poor patient survival is well established. In this study, in addition to demonstrating the expression of GRP78 in tumor tissue, we investigated the immune response against GRP78 in a group of patients with different progression stages of malignant melanoma. Furthermore, we analyzed the glycosylation status of GRP78 immunoglobulin (Ig) G autoantibodies at these stages and evaluated their capacities to affect the protein B-dependent protein kinase signaling pathway and unfolded protein response signaling mechanisms, all known to promote malignant melanoma cell proliferation and survival. We found that progression of disease correlates not only with enhanced expression of GRP78 in the tumor but also with an increase in GRP78 autoantibody serum titers in these patients. We also found that the glycosylation status of anti-GRP78 IgG changes as the disease progresses. The anti-GRP78 IgG is abnormally glycosylated in the Fc region and asymmetrically glycosylated in the Fab region. We demonstrate that hyperglycosylated anti-GRP78 IgGs stimulate cell proliferation through protein B-dependent protein kinase signaling pathways. They also mimic the effects of a 2 -macroglobulin on the upregulation of GRP78 and X-box binding protein 1, activating transcription factor 6 a, and serine/threonine-protein kinase/endoribonuclease precursor a as endoplasmic reticulum stress biomarkers and show no effect on expression or activation of caspases 3, 9, or 12. In conclusion, the anti-GRP78 IgG autoantibodies downregulate apoptosis and activate unfolded protein response mechanisms, which are essential to promote melanoma cell growth and survival.
A correlation between expression of the glucose-regulated protein of 78 kDa (GRP78) in malignant melanoma tumors and poor patient survival is well established. In this study, in addition to demonstrating the expression of GRP78 in tumor tissue, we investigated the immune response against GRP78 in a group of patients with different progression stages of malignant melanoma. Furthermore, we analyzed the glycosylation status of GRP78 immunoglobulin (Ig) G autoantibodies at these stages and evaluated their capacities to affect the protein B-dependent protein kinase signaling pathway and unfolded protein response signaling mechanisms, all known to promote malignant melanoma cell proliferation and survival. We found that progression of disease correlates not only with enhanced expression of GRP78 in the tumor but also with an increase in GRP78 autoantibody serum titers in these patients. We also found that the glycosylation status of anti-GRP78 IgG changes as the disease progresses. The anti-GRP78 IgG is abnormally glycosylated in the Fc region and asymmetrically glycosylated in the Fab region. We demonstrate that hyperglycosylated anti-GRP78 IgGs stimulate cell proliferation through protein B-dependent protein kinase signaling pathways. They also mimic the effects of a 2 -macroglobulin on the upregulation of GRP78 and X-box binding protein 1, activating transcription factor 6 a, and serine/threonine-protein kinase/endoribonuclease precursor a as endoplasmic reticulum stress biomarkers and show no effect on expression or activation of caspases 3, 9, 
Introduction
The circulation of autoantibodies against antigens expressed by tumors is a common occurrence in cancer patients. One of these antigens, the glucose-regulated protein of 78 kDa (GRP78), induces synthesis of autoantibodies in prostate cancer patients whose anti-GRP78 immunoglobulin (Ig) G serum titers are positively correlated with disease progression and shorter overall survival [1] . In prostate cancer, the GRP78 antigenic region corresponds to an epitope defined by the tertiary structure peptide CNVSKDSC, which mimics a complementary tertiary structure site in GRP78 (1) . This site was found to be localized in the GRP78 primary amino acid sequence LIGRTWNDPSVQQDIKFL (Leu 98 -Leu 115 ), which is also a binding site for its physiologic agonist, activated a 2 -macroglobulin (a 2 M*) [2] . Autoantibodies to GRP78 are also found in patients with ovarian cancer, and their presence has also been linked to poor prognosis and poor survival [3] . In a recent study in patients with malignant melanoma, the expression of GRP78 in tumor tissue was found to correlate with poor overall patient survival, but the presence of GRP78 autoantibodies, their epitope specificity, or their mechanisms of action were not assessed [4] .
In prostate and ovarian cancer, the immune response against GRP78 is paradoxical in the sense that overexpression of this protein, rather than preventing tumor growth, induces growth and progression of the tumor [1, 3] . As binding of these autoantibodies to GRP78 promotes tumor growth, they behave as tumorigenic rather than as antitumor immune mediators. In a recent report [5] , we show a causal link between a humoral response to GRP78 and the progression of cancer in a murine malignant melanoma model.
The reaction of GRP78 with its autoantibodies induces an autoimmune response that supports tumor-specific tolerance [6] , a phenomenon extensively investigated and attributed to aberrant IgG glycosylation in women with ovarian and endometrial cancers [7] . Aberrantly glycosylated antibodies show an asymmetric oligosaccharide structure due to the presence of an oligosaccharide residue of the high-mannose type, inserted in the Fd fragment of the H chain of one of the Fab regions [8] . The addition of an N-linked carbohydrate chain to Asn 58 to only one of the IgG heavy chains [9] converts these IgGs in univalent molecules because one of the paratopes is blocked by a carbohydrate chain. When specific to selfantigens, they are beneficial for the host because they block antigens and cannot trigger the biological reactions responsible for antigenic damage [10] . Taking this into consideration, it is possible to isolate these asymmetric IgG molecules from the total IgG present in normal or immune sera using concanavalin A-Sepharose chromatography [11] . Similar antibodies are also present in the serum from pregnant women and have been suggested as contributing to the suppression of maternal immune responses against the fetus [10] .
GRP78 is essential as a sensor for endoplasmic reticulum (ER) stress. The pathogenic mechanism by which increased GRP78 expression results in an adverse prognosis in cancer is related to its capacity to limit apoptosis during ER stress or the unfolded protein response (UPR) [4] . In a previous study [2] , we demonstrated that GRP78 autoantibodies from prostate cancer patients modulate proliferation of human prostate cancer cells in vitro. These antibodies mimic the proliferative effects induced by a 2 M* in prostate cancer cells [2] . As we have already shown that anti-GRP78 autoantibodies from tumorbearing or GRP78-immunized mice significantly accelerate tumor growth and induce protein B-dependent protein kinase (Akt) phosphorylation and proliferation of mouse B16F1 and human DM6 melanoma cells [5] , we initiated a new study to assess the mechanisms by which anti-GRP78 autoantibodies stimulated human malignant melanoma growth. First, we evaluated their titers and epitope specificity, followed by a search of a possible aberrant glycosylation pattern in anti-GRP78 autoantibodies from a population of 32 patients with malignant melanoma. We analyzed the expression of GRP78 in different stages of primary and metastatic malignant melanoma progression in paraffin-fixed tumor sections and cell lines created from these tumors. Antibodies against this protein were identified in serum samples from this population. As the disease progressed, we observed a change in the ratio of oligosaccharides containing high mannose in both the Fab and Fc regions of the anti-GRP78 IgGs from these patients. These antibodies bind very efficiently to human melanoma cells and induce rapid cell proliferation in vitro. We also evaluated the capacity of the aberrantly glycosylated IgGs to induce Akt phosphorylation and unfolded protein response signaling mechanisms in human malignant melanoma cells. Our results suggest aberrant glycosylation as a possible mechanism by which anti-GRP78 autoantibodies promote malignant melanoma cell proliferation and survival.
Materials and methods

Proteins and peptides
Recombinant GRP78, a gift from Dr Sylvie Y. Blond from the University of Illinois at Chicago, was prepared as previously described [12] . Keyhole limpet hemocyanin (KLH) was purchased from Sigma (St Louis, Missouri, USA). The CNVSDKSC peptide was purchased from Genemed Synthesis Inc. (San Francisco, California, USA). The CNVSDKSC peptide of GRP78 was conjugated to KLH through its terminal cysteine residues by the heterobifunctional cross-linker sulfosuccinimidyl 4-(Nmaleidomethyl)-cyclohexane-1-carboxylate (Pierce, Rockford, Illinois, USA) and quantified as previously described [2, 13] . Protein A/G was purchased from Pierce Biotechnology (Rockford, Illinois, USA). Pure Canavalia ensiformis lectin (concanavalin A) conjugated to alkaline phosphatase was purchased from EY Laboratories Inc. (San Mateo, California, USA). A glycan differentiation kit containing a digoxigenin-labeled Galanthus nivalis lectin was purchased from Roche Diagnostics (Indianapolis, Indiana, USA).
Patients
Blood samples were taken from 32 patients at Duke University Medical Center who were suffering from invasive malignant melanoma. Control samples (n = 15) were obtained from blood donor volunteers. The average age within the patient group was 39 years (range: 14-62 years) the majority of patients were males (1 : 10 F: M ratio). The anatomic locations of the malignant melanomas in order of frequency were as follows: back (12 cases), lower extremity (six cases), upper extremity (four cases), chest (four cases), neck (two cases), and unknown (two cases). All patients had nodal involvement by malignant melanoma whereas 40% of the population had visceral metastasis. The Breslow thickness average was 5.57 mm (range: 1.78-13 mm). Patients were classified according to criteria implemented by The American Joint Committee on Cancer Staging for melanoma of the skin. Six of these tumors were stage IIIa, four were at stage IIIb, nine were at stage IIIc, and 17 were at stage IV.
Antibodies
Human serum anti-GRP78 IgG was purified by affinity chromatography on Protein A/G-Sepharose, followed by immunoadsorption to the GRP78 peptide CNVSDKSC coupled to carboxymethyl Sepharose [2] . Nonimmune human IgG was purchased from ICN Pharmaceuticals Inc. (Aurora, Illinois, USA). Horseradish peroxidase (HRP)-conjugated IgG against human IgG, Fab-specific or Fc-specific, were purchased from Sigma (St Louis, Missouri, USA). Alexa Fluor 488-conjugated to goat antihuman IgG was purchased from Invitrogen (Eugene, Oregon, USA).
Analysis of serum anti-GRP78 autoantibody
Autoantibodies against GRP78 in the serum of melanoma cancer patients were assayed by an enzyme-linked immunosorbent assay (ELISA) technique in 96-well culture plates coated with murine recombinant GRP78 or the GRP78 peptide CNVSDKSC conjugated to KLH (5 mg/ml) in 0.1 mol/l Na 2 CO 3 , 0.01% NaN 3 , pH 9.3. Incubation of these plates with serum samples and data analysis was carried out as previously described [2] . Quantification of the titers of anti-GRP78 autoantibodies was done using three dilutions of the patient sera (1 : 5000, 1 : 1000, and 1 : 500). Calibration curves were constructed with the two GRP78 antigens. We determined a linear range of response between 0 and 100 mg/ml using isolated anti-GRP78 IgG from patients. Patient serum (50 ml, 1 : 500 dilution) was used in all assays. At this dilution all titers fall within the linear range of the calibration curves. In brief, plates were incubated with patient serum at 371C for 2 h in 200 ml of 10 mmol/l sodium phosphate, 0.1 mol/l NaCl (pH 7.4) containing 0.05% Tween 80 [phosphate buffered saline (PBS)-Tween], and then rinsed with PBS-Tween. Plates were then incubated at 371C for 2 h with an affinity purified antihuman IgG polyclonal alkaline phosphatase-conjugated rabit IgG in PBS-Tween. After rinsing the plates with PBS-Tween, 200 ml of alkaline phosphatase substrate (1 mg/ml p-nitrophenylphosphate) in 0.1 mol/l glycine, 1 mmol/l MgCl 2 , 1 mmol/l ZnCl 2 (pH 10.4) was added to the plate, and absorbance was monitored at a wavelength of 405 nm using an Anthos Labtec Kinetic Plate reader (Eugendorf, Austria). Bound IgG expressed as DA 405/min was converted to microgram per milliliter using calibration curves constructed with purified patient anti-GRP78 IgGs.
Assay of a-D-mannose residues of anti-GRP78 autoantibodies Specific detection of a-D-mannose residues of IgG autoantibodies against GRP78 was performed with a glycan differentiation kit (Roche Diagnostics, Indianapolis, Indiana, USA) on 96-well plates coated with the CNVSDKSC peptide conjugated to KLH, as described above. For these assays, serum aliquots (50 ml, 1 : 500 dilution) were added in triplicate in 200 ml final volume of PBS-Tween and incubated 2 h at 371C, followed by rinsing in PBS-Tween and incubation with a digoxigeninlabeled Galanthus nivalis agglutinin, which recognizes 'high mannose' N-glycan chains [14] for 90 min at 371C. After rinsing with PBS-Tween to remove unbound lectin, the plates were incubated for 1 h at 371C with a polyclonal sheep antidigoxigenin Fab fragment conjugated with alkaline phosphatase (7 units/well in 200 ml PBS-Tween) followed by rinsing with PBS-Tween. Detection of bound lectin was performed by incubating the plates with 200 ml alkaline phosphatase substrate (1 mg/ml p-nitrophenylphosphate) in 0.1 mol/l glycine, 1 mmol/l MgCl 2 , 1 mmol/l ZnCl 2 , pH 10.4. Absorbance was monitored at 405 nm.
The total D-mannose concentration of the specific anti-GRP78 IgG was calculated from calibration curves constructed with the glycoprotein carboxypeptidase Y [15] as suggested by the kit manufacturer.
Histologic and immunohistochemistry
For immunohistochemical staining, 4-5 mm sections were preheated in 1 Â Dako Target Retrieval solution, pH 6.1, and heated for 20 min in a 1001C water bath. After antigen retrieval, the tissue sections and retrieval solution were allowed to cool for 20 min. The slides were washed with several changes of deionized water and placed in Tris buffered saline. Tissue sections were blocked with 5% nonimmune horse serum. Excess serum was drained from each slide and affinity purified GRP78 goat polyclonal antibody (N-20) diluted 1 : 400 was applied and incubated for 1 h. Detection of the bound primary antibody was accomplished by linking with biotinylated horse antigoat IgG. Visualization of the bound immune complex was obtained using 3,3 0 -diaminobenzidine tetrahydrochloride or permeant 3-amino-9-ethylcarbazole. Sections were counterstained with modified Harris hematoxylin, followed by traditional dehydration, clearing, and mounting.
Cell cultures
The melanoma tumor cell line, DM6, was a gift from Dr Hilliard F. Seigler, Department of Immunology, Duke University Medical Center. This cell line was established in vitro from melanoma-involved lymph nodes [16] . These cells conserve the properties of the original tumor and express S-100, HMB-45, and MART-1, which are melanocytespecific biological markers for metastatic melanoma [17] .
Immunofluorescence microscopy DM6 cells were plated at 5 Â 10 5 cells/ml on Lab-Tek II Chamber Slides (Nalge Nunc International, Naperville, Illinois, USA) and allowed to adhere overnight. Cells were incubated for 1 h at 41C in PBS containing 2% bovine serum albumin, 0.2 mg/ml goat IgG, and 0.01% NaN 3 (staining buffer), followed by incubations with anti-GRP78 or nonimmune human IgGs (2 mg/ml) for 1 h at 41C. Cells were washed in PBS and incubated for 1 h with an Alexa Fluor 488 conjugated to goat antihuman IgG before washing and fixing in 4% paraformaldehyde. Immunofluorescence microscopy was performed using an Olympus BX-60 microscope (Olympus, Lake Success, New York, USA).
Antibody binding studies by flow cytometry
DM6 cells were detached from the culture flasks (75 cm 2 ) by incubation for 5 min at 371C with Ca 2 + -free and Mg 2 + -free PBS containing 4 mmol/l EDTA and pelleted. The cells (1 Â 10 6 /ml) were washed with PBS before resuspension in ice-cold PBS containing 3% bovine serum albumin (staining buffer). The cell suspensions (500 ml) were incubated 30 min with human anti-GRP78 IgG (10 mg/ml). An equivalent quantity of nonimmune human IgG was used as an isotype control. At this time the cells were washed, pelleted, and resuspended in 500 ml of ice-cold staining buffer. The cell suspensions were incubated for 30 min in the dark with AF488conjugated goat antihuman IgG. The cells were washed twice with ice-cold staining buffer, resuspended in the same buffer, and stored in the dark at 41C for 10 min until analysis. Staining with propidium iodide (2 mg/ml) was performed immediately before flow cytometric analysis to exclude dead cells. Flow cytometry was conducted using the Guava EasyCyte Plus system (Guava Technologies, Hayward, California, USA). Data analysis and histogram preparation was performed using FlowJo 8.6.3 software (Treestar Inc., Ashland, Oregon, USA).
DM6 cell proliferation assays
DM6 cells suspended in RPMI 1640 containing 5% fetal bovine serum at a density of 1 Â 10 5 cells/ml were plated in 96-well culture plates (0.1 ml/well) containing increasing concentrations of human melanoma patient anti-GRP78 IgG at a final volume of 0.2 ml/well. Cell proliferation was determined as previously described [2] .
Stimulation of DM6 melanoma cells with differentially glycosylated immunoglobulin G fractions
DM6 cells plated in 96-well cell culture plates grew until roughly 90% confluent. After 5 h of serum starvation, we applied 100 ml of RPMI with 100 pM concanavalin A Sepharose-separated IgG from individual melanoma patients. After 15 min stimulation at 371C, the cells were rinsed twice with ice-cold PBS and then lysed in 100 ml per well of PBS with 1 mmol/l EDTA, 1M urea, protease inhibitors, and phosphatase inhibitors (Halt Protease Inhibitor Cocktail, Thermo Scientific, Rockford, Illinois, USA) for 15 min on ice. Samples were centrifuged in v-bottom plates at 2000 g for 5 min, transferred to a clean plate, and diluted 1 : 1 with PBS with 1 mmol/l EDTA, 0.5% Triton X-100 and 5 mmol/l NaF. 100 ml aliquots of each sample were used directly for ELISA quantitation of total and phosphorylated Akt (R&D Systems Inc., Minneapolis, Minnesota, USA) according to the manufacturer's protocol. All conditions were done in triplicate and performed twice. Measurements of phospho-Akt were normalized to total Akt levels.
SDS-polyacrylamide gel electrophoresis and immunoblotting
Isolated IgGs were analyzed on 12% polyacrylamide gels (1.2 mm thick, 14 Â 10 cm) containing 0.1% SDS under reducing conditions. The IgG-derived Fc fragments were analyzed under reducing conditions on 15% polyacrylamide gels. A discontinuous Laemli buffer system was used [18] . Transfer to nitrocellulose membranes by the western blot method was carried out as described by Towbin et al. [19] . The molecular weights were assesed using a set of dye-conjugated Mr markers (Fermentas Life Sciences, Glen Burnie, Maryland, USA).
Proteolytic digestion of immunoglobulin G molecules and analysis of their fragments
Singly purified anti-GRP78 IgGs were digested with papain to identify the region in the molecule affected by aberrant glycosylation. The IgGs (200 mg) in 25 mmol/l phosphate, pH 7.0, containing 10 mmol/l EDTA and 10 mmol/l cysteine were incubated with 50 mg of immobilized papain (Pierce Chemical Co., Rockford, Illinois, USA) for 6 h at 371C. The Fab and Fc fragments and undigested IgG were separated from the immobilized papain using Micro Bio-Spin Chromatography Columns (Bio-Rad, Hercules, California, USA). The digested material was applied to an immobilized protein A/G column equilibrated with PBS. The column was washed with PBS and the eluate was collected (5 ml). This unbound fraction contained the Fab fragments. The Fc fragments were eluted from protein A/G with 20 mmol/l glycine-HCl, pH 3.0, followed by dialysis against PBS, and concentrated using an Amicon centrifugal concentrator with a 10 kDa cutoff (Millipore Corporation, Bedford, Massachusetts, USA). The Fab and Fc fragments were transferred to nitrocellulose membranes, reacted with specific rabbit antihuman Fab or Fc IgGs conjugated to HRP and then developed with the HRP substrate 4-chloro-1-naphtol. Densitometric analysis was performed using the program Image Quant for Windows, Version 5.2, from Molecular Dynamics (Sunnyvale, California, USA).
Removal of N-linked oligosaccharides from GRP78 autoantibodies
Anti-GRP78 IgG (1 mg) in 20 mmol/l sodium phosphate, pH 7.5, containing 150 mmol/l NaCl and 0.02% sodium azide, was incubated with 100 milliunits of recombinant N-glycanase (peptide-N-glycosidase F) from Glyko Inc., (Novato, California, USA) at 371C for 16 h. The Ndeglycosylated anti-GRP78 IgG was then separated from the N-glycanase by chromatography on an immobilized protein A/G column equilibrated with PBS as described above.
Effect of GRP78 autoantibodies on expression of proteins of unfolded protein response signaling pathways DM6 cells were plated on six-well plates at a concentration of 3 Â 10 5 cells per well. When cells reached 90% confluency, anti-GRP78 IgG, nonimmune IgG control, or N-deglycosylated anti-GRP78 IgG (1 mg/ml) in serumfree Dulbecco's modified Eagle's medium was added to the DM6 cell monolayers and incubated at 371C for 24 h in triplicate. After aspirating culture medium and washing wells with PBS, cells were lysed with radioimmuno precipitation assay buffer (150 mmol/l NaCl, 0.5% sodium deoxicholate, 50 mmol/l Tris-HCl pH 8.0, 1% NP-40, 0.1% SDS, 1 Â Halt protease inhibitor) and sonicated. Protein concentration was determined using the bicinchonic acid procedure and loaded (35 mg) on each well of a 4-12% bis-tris gel (NuPAGE, Invitrogen). Proteins were then electroblotted to nitrocellulose membranes and singly reacted with antibodies against activating transcription factor 6 a (ATF-6a), serine/threonine-protein kinase/endoribonuclease precursor (IRE1a), X-box binding protein 1 (XBP-1), N20 GRP78, procaspase 12, cleaved caspase 12, procaspase 9, cleaved caspase 9, cleaved caspase 3, and b-actin purchased from Santa Cruz Biotechnology (Santa Cruz, California, USA). The detection and quantification of these proteins in immunoblots were performed by electrochemical fluorination and phosphorimaging using a STORM 860 ECF Imager System from General Electric (Piscataway, New Jersey, USA).
Statistics
The levels of anti-GRP78 IgG were evaluated by a Student's t-test using the program SYSTAT for Windows: Statistics, Version 11 (Systat, Inc., Evanston, Illinois, USA).
Results
Anti-GRP78 immunoglobulin G levels and analyses of their D-mannose content in serum from malignant melanoma patients These analyses were performed in malignant melanoma patients (n = 32) divided into three groups according to the growth phase of their tumors. Group 1 (n = 6) consisted patients with stage IIIa disease. Group 2 (n = 9) represents patients with stage IIIb and IIIc disease. Group 3 (n = 17) consisted patients with stage IV disease. Their serum titers were compared with a group of controls (n = 15). In a previous report [2] , we found that circulating anti-GRP78 IgG autoantibodies in patients with prostate cancer react mainly with the CNVSDKSC peptide, localized in the GRP78 N-terminal region. We performed similar assays with malignant melanoma patient serum using plates coated with total murine recombinant GRP78 and found titer values (data not shown) within the same order of magnitude of those determined using an ELISA assay with this peptide. The results in our patient groups (Fig. 1a) show titer increases that are statistically significant between the three groups of patients and controls (means, 4.4 ± 0.84, 6.38 ± 2.54, 8.39 ± 3.03, and 1.33 ± 1.05 mg/ml, respectively; P < 0.005). These experiments demonstrate that most of the reactivity (>90%) resides in the N-terminal region of GRP78, thereby confirming our previous observations in patients with prostate cancer [2] . Then, we assessed the D-mannose content of anti-GRP78 autoantibodies using ELISA plates coated with this peptide and the Galanthus nivalis lectin as a detecting reagent. The results (Fig. 1b) show a significantly greater reactivity of this lectin with patient anti-GRP78 antibodies from the three groups compared with the control population (means, 56.2 ± 3.87, 73.58 ± 5.54, 78.33 ± 5.07, and 11.27 ± 1.23 ng D-mannose/mg anti-GRP78 IgG, respectively; P < 0.005).
Specific identification of aberrant anti-GRP78 immunoglobulin G in the serum of malignant melanoma patients
First, total IgG was isolated from each individual serum by chromatography on protein A/G-agarose, followed by chromatography on concanavalin A Sepharose to separate the IgG populations with high and low D-mannose contents [11] . Then, similar concentrations (100 ng/well) of the three IgG populations were incubated in ELISA plates coated with the CNVSDKSC peptide as described above. Binding of anti-GRP78 was calculated and expressed as a percentage of total IgG. The results for the three groups of patients ( Fig. 2a) show that the majority of the anti-GRP78 autoantibodies are found in the fractions with affinity for concanavalin A. We also examined the capacity of these IgGs (100 pM) to induce phosphorylation of Akt in DM6 malignant melanoma cells (Fig. 2b) . These data show increased p-Akt in cells incubated with the IgG fraction with high affinity for concanavalin A, whereas the IgG fraction not retained by concanavalin A shows only a moderate effect. Next, we took IgG samples (100 pM) from each patient group and incubated these IgGs with this peptide (500 pM) before addition to DM6 cells. The results (Fig. 2c ) from a representative high mannose-containing sample in the three groups of patients show that GRP78 in solution inhibits the effect of the IgG, thereby confirming that anti-GRP78 autoantibodies are responsible for Akt phosphorylation.
Electrophoretic analyses of aberrant anti-GRP78 immunoglobulin Gs in malignant melanoma patients during the clinical course of the disease
A large percentage of the aberrantly glycosylated IgGs appear to be directed against GRP78. We investigated any changes in the glycosylation of the GRP78 autoantibody in the serum of three patients during a 9-month period. Serum samples were obtained at the time of diagnosis, followed by samples at 7 and 9 months. The specific anti-GRP78 IgGs were purified by immunoaffinity chromatography on CNVSDKSC-carboxyhexyl-Sepharose. During this period, the antibody serum concentration increased significantly from 7.23 ± 2.54, 9.35 ± 3.21, and 8.76 ± 2.18 mg/ml at the beginning of the study to 12.47 ± 2.83, 17.42 ± 3.51, and 18.93 ± 3.62 mg/ml, respectively, for the three patients at 9 months (P < 0.001).
Each single anti-GRP78 IgG was digested with papain and analyzed by SDS-polyacrylamide gel electrophoresis. Representative IgG fragments obtained from patient 1 are shown. Fab or Fc protein fragments from IgG purified from three patients was quantified by densitometric analyses, and the change in size was expressed as the ratio between the upper (U) and lower (L) protein bands compared with normal IgG fragments. The Fab fragments from melanoma anti-GRP78 IgG exhibited a 55 kDa heavy chain and the progressive appearance of a 65 kDa band, when compared with normal IgG during this period (Fig. 3a) . The Fc fragments show an even more dramatic shift in molecular weight from the control Fc (Fig. 3b) , thereby suggesting that both the Fab and the Fc region of the anti-GRP78 IgG of melanoma patients is aberrantly glycosylated.
Histologic and immunohistochemical studies
Expression of GRP78 in tissue from these patients was qualitatively evaluated during this period. Progression of the disease was examined by histologic and immunohistochemical analyses on three representative patients. As similar changes were observed in all three patients tested, data are shown only for a representative patient (patient 3, 18.93 ± 3.62 mg/ml of anti-GRP78 IgG). A 20-year-old male patient was diagnosed with invasive malignant melanoma of the left great toe. The latter was amputated at the metatarsal phalangeal joint. Gross examination of the specimen showed a subungueal ill-defined ulcerated mass measuring 4.5 cm in greatest dimension. Histologic examination of this area revealed a proliferation of enlarged melanocytes with high nuclear to cytoplasmic ratio and prominent nucleoli (Fig. 4a ). These severely atypical melanocytes exhibited confluent growth with a significant pagetoid spread. The tumor invaded the dermis and subcutaneous tissue and was diagnosed as a malignant melanoma at Clark level V with a Breslow depth of 13 mm. High mitotic rate was seen (13 mitosis per mm 2 ) (Fig. 4a arrow) . Bone involvement was noted ( Fig. 4c and e ). Seven months after the amputation, a left groin node dissection revealed malignant melanoma replacing four of 25 lymph nodes. Sections from the involved lymph nodes showed melanocytes sharing the same histologic phenotype with those seen in the primary amputation (Fig. 4g ).
Two months after the resection of the left groin lymph nodes, the patient showed progressive disease. Two of 11 left lymph nodes from the iliac region, and one of seven from the obturator region showed metastatic malignant melanoma. Histologic sections showed lymph node parenchyma replaced by severely atypical melanocytes. GRP78 was expressed in malignant melanoma cells in the epidermal and in the dermal compartments of the primary tumor (Fig. 4b) . Tumor cells maintained expression of the protein at the level of the bone invasion ( Fig.  4d and f) . GRP78 was also expressed in the cytoplasm of malignant melanocytes in the lymph node metastases; however, the degree of expression is lower than in the primary tumor (Fig. 4h ).
Analyses of binding of melanoma anti-GRP78 IgG to human malignant melanoma cells by immunofluorescence microscopy and flow cytometry. We studied binding of the malignant melanoma anti-GRP78 IgG to DM6 melanoma cells grown on Chamber Slide Systems. Immunofluorescence staining of nonpermeabilized DM6 cells incubated with anti-GRP78 IgG (Fig. 5a ) or nonimmune human IgG (Fig. 5b) showed surface expression of GRP78 on these cells. These results were confirmed by flow cytometric analyses with anti-GRP78 IgG (Fig. 5c ).
Effect of melanoma anti-GRP78 immunoglobulin G on human melanoma cell proliferation and Akt phosphorylation
Cell proliferation was determined as described under Materials and methods. Total anti-GRP78 IgG was purified by affinity chromatography from a serum pool (5 ml) mixing 0.5 ml of serum from each patient. DM6 cells were incubated for 72 h in RPMI 1640 culture medium containing 5% fetal bovine serum with melanoma anti-GRP78 at 50 pM (Fig. 6a3 ) or 100 pM (Fig. 6a4) . As a positive control, they were incubated with 100 pM prostate cancer anti-GRP78 IgG (Fig. 6a2) . As a negative control, they were incubated with 100 pM nonimmune human IgG (Fig. 6a1 ). Under these conditions, DM6 cells show statistically significant increases in proliferation induced by both autoantibodies when compared with cells incubated with the nonimmune human IgG (Fig. 6a2 , P < 0.0001; Fig. 6a3 , P < 0.004; Fig. 6a4 , P < 0.0001).
For Akt phosphorylation assays, DM6 cells were incubated with a single concentration (100 pM) of the anti-GRP78 or nonimmune human IgG and their fragments (Fig. 6b ).
Both the intact anti-GRP78 IgG (Fig. 6b1 ) or its Fab fragment (Fig 6b2) induce Akt phosphorylation, whereas the melanoma anti-GRP78 Fc fragment (Fig 6b3) or the nonimmune IgG or its Fab and Fc fragments (Fig. 6b4,  Fig. 6b5, and Fig. 6b6 , respectively) do not have any effect. Effect of anti-GRP78 IgG on unfolded protein response signaling and caspase activation pathways
We have previously observed that activated a 2 M* induces expression of GRP78 in a dose-dependent manner [20] . As observed above, the malignant melanoma anti-GRP78 IgG-stimulated DM6 cell proliferation mimics that induced by a 2 M*. Then, we measured expression of GRP78, XBP-1, ATF-6a, and IRE1a as ER stress biomarkers at a single concentration (1 mg/ml) of anti-GRP78 IgG, nonimmune IgG control or N-deglycosylated anti-GRP78 IgG in serum-free Dulbecco's modified Eagle's medium. The analysis (Fig. 6c) shows increase of GRP78, XBP-1, ATF-6a, and IRE1a in cells incubated with native anti-GRP78 IgG, whereas the N-deglycosylated or nonimmune control IgGs did not affect the levels of these ER stress biomarkers. During ER stress, caspases are activated through cleavage by upstream caspases, which lead to apoptotic cell death [21] . Activation of caspase 12 is specific to ER stress. Once activated, the catalytic subunit of caspase 12 is released into the cytosol, in which it activates the caspase-9 cascade. For this reason, we also quantified levels of caspase 12, cleaved caspase 9, and cleaved caspase 3 (Fig. 6c ). We observed no activation of caspase 12 or caspase 9 in DM6 cells incubated with either fully glycosylated or N-deglycosylated anti-GRP78 IgG. We also analyzed UPR signaling on cells stimulated with a 2 M* ( Fig. 6d ) and observed increases of GRP78, XBP-1, ATF-6a, and IRE1a in DM6 cells, thus confirming previous observations in prostate cancer 1-LN cells [20] . Similarly, DM6 cells incubated with a 2 M* show no significant activation of caspases 3, 9, and 12 when compared with control cells incubated with culture medium alone. These results suggest that the anti-GRP78 IgG stimulates cell proliferation through upregulation of ER stress biomarkers in a manner analogous to that of a 2 M* that leads to prevention of apoptosis. Furthermore, they also suggest that hyperglycosylation of the anti-GRP78 IgG is necessary for this mechanism.
Discussion
High levels of GRP78 expression in many types of cancers, such as breast [22] , lung [23] , gastric [24] , colonic [25] , prostatic [26] hepatocellular carcinoma [27] , and malignant melanoma [4] have been correlated with an adverse prognosis. Conversely, augmented expression of GRP78 is also associated with a better prognosis in neuroblastoma [28] and is an indicator of favorable responsiveness to chemotherapy in breast cancer [29] and malignant gliomas [30] . These discrepancies demonstrate that expression of GRP78 needs to be carefully analyzed before considering it as a reliable prognostic biomarker in cancer. However, it is possible to associate GRP78 expression with the presence in the circulation of very high titers of an autoantibody against GRP78 in prostate and ovarian cancer [1, 3] . Expression of GRP78 in malignant melanoma was recently assessed [4] , but these investigators did not correlate their findings with the autoimmune response to GRP78. We recently demonstrated a causal link between a humoral response to GRP78 and the progression of cancer in a murine malignant melanoma model [5] .
In this study, we assessed the titers of specific anti-GRP78 IgG autoantibodies in patients with malignant melanoma (n = 32), divided in three groups according to tumor stage, and found that their levels are significantly higher than those found in the control population. The malignant melanoma anti-GRP78 autoantibodies recognize preferentially the primary amino acid sequence CNVKSDKSC, which contains a tertiary structural motif mimicking an epitope in GRP78 [2] . Their binding to the Galanthus nivalis lectin, which interacts with mannose-rich oligosaccharides [13] , not normally present in circulating IgG, suggests that they are aberrantly glycosylated.
The highly mannosylated IgG fraction containing a greater percentage of GRP78 autoantibodies induced larger Akt phosphorylation levels in DM6 human melanoma cells when compared with the normally glycosylated IgG fraction. Akt phosphorylation was also stimulated by affinity purified malignant melanoma anti-GRP78 IgG, thereby suggesting their involvement in increased Akt phosphorylation levels. It is known that Akt deregulation promotes malignant melanoma cell proliferation and survival [31] .
We correlated expression of GRP78 protein with autoantibody titers during the progression of malignant melanoma in three patients at disease stages III and IV. GRP78 was found in radial and vertical growth phases of primary malignant melanomas, thereby suggesting its involvement in primary tumor development. Furthermore, GRP78 continues to be expressed in malignant melanoma cells after they acquire metastatic potential involving lymph nodes and viscera. At the same time, there is an increase in titers of antibodies against this protein in serum, suggesting a correlation between these two events when the aggressiveness of malignant melanoma intensifies.
Analyses of purified anti-GRP78 IgGs from serum of these three patients, produced during this period, show that Fab and Fc regions increase in their glycosylation. The proportion of aberrantly glycosylated Fab fragment (55-65 kDa) is similar to that observed in ovarian cancer [7] , whereas aberrant glycosylation, leading to a change in size of the Fc fragment (27) (28) (29) (30) (31) (32) (33) , is almost complete in the malignant melanoma anti-GRP78 IgG. Changes in size of the Fc fragment indicate that the Asn 297 N-linked oligosaccharide is the target of this phenomenon, which probably results from lack of processing of D-mannosyl residues, thereby adding to the size of this region [9] . The presence of two Fab chains is an indication of asymmetric glycosylation. Therefore, the anti-GRP78
IgG is asymmetrically glycosylated at the Fab region and aberrantly glycosylated at the Fc. Functionally, the asymmetric Fab glycosylation matters, as reflected by its capacity to induce phosphorylation of Akt. A relationship between changes in the N-linked glycosylation of human serum IgG and progression of prostate, lung, and gastric cancer has also been reported [32] [33] [34] .
The asymmetrical glycosylation of the anti-GRP78 IgG is essential for upregulation of GRP78 and XBP-1, ATF-6a, and IRE1a as ER stress biomarkers [20] . As a 2 M* upregulates these biological markers in DM6 cells in a manner similar to that observed with prostate cancer 1-LN cells [20] , we infer that the anti-GRP78 IgG also mimics the effects of a 2 M* in these cells. Similarly, a 2 M* did not promote activation of caspase 3, caspase 9, or caspase 12, thereby confirming the function of these autoantibodies to GRP78 as protective to tumor cells.
In summary, we have shown that treatment of DM6 malignant melanoma cells with antibodies to GRP78 isolated from malignant melanoma patients promotes their proliferation by activating Akt. To overcome the stress induced by rapid growth in the presence of asymmetrically glycosylated autoantibodies to GRP78 which mimic the function of a 2 M*, these cells trigger UPR signaling which in turn may be regulated by ERassociated and plasma membrane-associated GRP78.
